- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Enthesis.
Displaying page 1 of 1.
| EudraCT Number: 2017-000901-19 | Sponsor Protocol Number: PSA‐PI‐006421 | Start Date*: 2017-09-11 |
| Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | ||
| Full Title: Evaluation of the clinical and echographic response to Apremilast through clinical evaluation and through a joint-periarticular-nail echographic index in patients with active psoriatic arthritis. | ||
| Medical condition: Psoriasic arthritis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-003887-39 | Sponsor Protocol Number: P1200_46 | Start Date*: 2020-10-29 |
| Sponsor Name:Cliniques universitaires Saint-Luc | ||
| Full Title: Molecular effects of Apremilast (Otezal) in synovial biopsies of patients with psoriatic arthisis | ||
| Medical condition: Psoriasis and Psoriatic Arthritis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-002631-33 | Sponsor Protocol Number: CAIN457A2209 | Start Date*: 2009-01-14 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis | |||||||||||||
| Medical condition: Ankylosing Spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA). | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) DE (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-004471-31 | Sponsor Protocol Number: I4V-MC-JAHX | Start Date*: 2019-06-13 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA) | |||||||||||||
| Medical condition: Juvenile Idiopathic Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001695-26 | Sponsor Protocol Number: FARM1275JK | Start Date*: 2018-09-12 | ||||||||||||||||
| Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI | ||||||||||||||||||
| Full Title: Monitoring the effectiveness and safety of biological drugs for treatment of psoriasis through evaluation of clinical and biological markers | ||||||||||||||||||
| Medical condition: Moderate to severe psoriasis and joint disease | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2008-002628-27 | Sponsor Protocol Number: CAIN457A2206 | Start Date*: 2009-01-15 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: Randomized, double-blind, placebo-controlled, multi-center, proof-of-concept study to assess the efficacy of AIN457 in patients with psoriatic arthritis | |||||||||||||
| Medical condition: Psoriatic arthritis (PsA), which belongs to seronegative spondyloarthropathies (SpA). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002018-29 | Sponsor Protocol Number: A3921165 | Start Date*: 2020-12-09 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS | |||||||||||||
| Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) PL (Completed) DE (Completed) BE (Completed) IT (Completed) NL (Prematurely Ended) SE (Prematurely Ended) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.